FMS Pengajuan SEC - Fresenius Medical Care AG - Depositary Receipt (Common Stock)- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1333141

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fresenius Medical Care AG - Depositary Receipt (Common Stock)

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 11, 2025	EX-99.2	Media contact Exhibit 99.2 Press Release Media contact Sven Jacobsen T +49 171 28 79 127 [email protected] Sabine Blessing T +49 171 74 81 259 [email protected] Contact for Analysts and Investors Ilia Kürten T +49 6172 685 966 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care announces first tranche of its share buyback program
August 11, 2025	EX-99.1	Bad Homburg v.d. Höhe, August 11, 2025 Exhibit 99.1 Bad Homburg v.d. Höhe, August 11, 2025 Disclosure pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052 Fresenius Medical Care AG (“FME”) disclosed on June 17, 2025 to conduct a share buyback program. The program is scheduled to commence on August 11, 2025, and to be completed within two years by August 10, 2027 (in
August 11, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-32749 FRESENIUS MEDI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) I
August 5, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-32749 FRESENIUS MEDI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) I
August 5, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025. Commission file number: 001-32 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025. Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant’s name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Addre
August 5, 2025	EX-10.3	Fresenius Medical Care AG Long-Term Incentive Plan 2025+ Exhibit 10.3 Annex I to the Management Board of Fresenius Medical Care AG Presentation: "Approval of the LTI 2025+ Plan Documents" dated July 15, 2025 Fresenius Medical Care AG Long-Term Incentive Plan 2025+ TABLE OF CONTENTS CLAUSE PAGE 1. Preamble and Purpose 3 2. Eligibility to Receive Performance Shares 4 3. Performance Shares 4 4. Grant of Performance Shares 5 5. Performance Targets 6 6. Vest
August 5, 2025	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2025 August 5, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2025 August 5, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results excl. special items
August 5, 2025	EX-99.1	Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025 Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025 ● Stro
August 5, 2025	EX-3.1	– NON-BINDING CONVENIENCE TRANSLATION – Exhibit 3.1 – NON-BINDING CONVENIENCE TRANSLATION – ARTICLES OF ASSOCIATION OF FRESENIUS MEDICAL CARE AG I. GENERAL TERMS Article 1Name and Registered Office (1) The name of the Company is: Fresenius Medical Care AG (2) The registered office of the Company is in Hof (Saale). Article 2Objects of the Company (1) The objects of the Company are: a) the development, production and distribution of, as w
June 27, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit
June 17, 2025	EX-99.3	Fresenius Medical Care AG New Segmentation June 17, 2025 Investor Relations phone: +49 6172 268 8795 email: [email protected] Exhibit 99.3 Fresenius Medical Care AG New Segmentation June 17, 2025 Investor Relations phone: +49 6172 268 8795 email: [email protected] Content: Segment information page 2 Revenue development by segment page 3 Reconciliation page 4 Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially fro
June 17, 2025	EX-99.2	Media Contact Exhibit 99.2 Press Release Media Contact Christine Peters T +49 160 60 66 770 [email protected] Sven Jacobsen T +49 171 28 79 127 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care Launches its Strategy FME Reignite with inc
June 17, 2025	EX-99.1	Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years Exhibit 99.1 Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years Bad Homburg, June 17, 2025 – Fresenius Medical Care AG (“Company”) has decided to conduct a share buyback program with a volume of EUR 1 billion (excluding ancillary costs) in tranches within two years after the start of the program. The execution of the share buyba
June 17, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Ind
June 5, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Ind
June 5, 2025	EX-99.1	Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S. Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Emanuela Cariolagian T +1 213 706 0051 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care Begins Broader U.S. Commercial
May 27, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Fresenius Medical Care AG (Exact name of the registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Fresenius Medical Care AG (Exact name of the registrant as specified in its charter) Germany 001-32749 04-3534941 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) Else-Kröner-Strasse 1, Bad Homburg, Germany D-61352
May 27, 2025	EX-1.01	Fresenius Medical Care AG Exhibit 1.01 Fresenius Medical Care AG Conflict Minerals Report This document, constituting Exhibit 1.01 to Form SD of Fresenius Medical Care AG, a German stock corporation (together with its subsidiaries, the Company, we, us, or our), is our Conflict Minerals Report for the year ended December 31, 2024, in accordance with Section 13(p) of the Securities Exchange Act of 1934, as amended and Rule 1
May 23, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 23, 2025	EX-99.2	Non-binding convenience translation Fresenius Medical Care AG Hof, Germany ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Notification pursuant to Section 49 (1) sentence 1 no. 2 German Securities Trading Act (“WpHG”) and In Exhibit 99.2 Non-binding convenience translation Fresenius Medical Care AG Hof, Germany ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Notification pursuant to Section 49 (1) sentence 1 no. 2 German Securities Trading Act (“WpHG”) and Information Announcement pursuant to Section 221 (2) sentence 3 German Stock Corporation Act (“AktG”) (Authorization to issue convertible b
May 23, 2025	EX-99.1	Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History Exhibit 99.1 Press Release Media Contact Christine Peters T +49 160 60 66 770 [email protected] Sven Jacobsen T +49 171 28 79 127 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com/de Fresenius Medical Care Annual General Meeting: Strong Performan
May 14, 2025	EX-99.2	Statement of the Management on the countermotion of the Association of Critical Shareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.) to item 3 of the agenda of the Annual General Meeting on May 22, 2025 Exhibit 99.2 Statement of the Management on the countermotion of the Association of Critical Shareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.) to item 3 of the agenda of the Annual General Meeting on May 22, 2025 The Management Board and the Supervisory Board stand by their proposed resolutions on the agenda and comment on the countermotion as follows: Resolution on the ap
May 14, 2025	EX-99.1	Countermotions submitted by the Association of Critical Shareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.) for the Annual General Meeting of Fresenius Medical Care AG on May 22, 2025 Exhibit 99.1 Countermotions submitted by the Association of Critical Shareholders (Dachverband der Kritischen Aktionärinnen und Aktionäre e.V.) for the Annual General Meeting of Fresenius Medical Care AG on May 22, 2025 Countermotion on Agenda Item 3: Resolution on the approval of actions of the members of the Management Board of Fresenius Medical Care AG for fiscal year 2024 The Association of Cr
May 14, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 6, 2025	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FIRST QUARTER 2025 May 6, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FIRST QUARTER 2025 May 6, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results excl. special items page 8 Outlook 2025 pag
May 6, 2025	EX-10.1	FINAL TERMS ENDGÜLTIGE BEDINGUNGEN Fresenius Medical Care AG EUR 600,000,000 3.125 per cent. Notes due December 8, 2028 EUR 600.000.000 3,125 % Schuldverschreibungen fällig 8. Dezember 2028 Series: 8, Tranche 1 Serien: 8, Tranche 1 issued pursuant to Exhibit 10.1 MIFID II PRODUCT GOVERNANCE / RETAIL INVESTORS, PROFESSIONAL INVESTORS AND ECPS TARGET MARKET – Solely for the purposes of each manufacturer’s product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties, professional clients and retail clients, each as defined in Directive
May 6, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 6, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission file number: 001-32749 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant’s name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Address
May 6, 2025	EX-99.1	Fresenius Medical Care starts 2025 with strong organic revenue and income growth Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care starts 2025 with strong organic revenue and income growth · Strong organic revenue growth1 of 5% driven by Care Enab
May 6, 2025	EX-10.2	FINAL TERMS ENDGÜLTIGE BEDINGUNGEN Fresenius Medical Care AG EUR 500,000,000 3.750 per cent. Notes due April 8, 2032 EUR 500.000.000 3,750 % Schuldverschreibungen fällig 8. April 2032 Series: 9, Tranche 1 Serien: 9, Tranche 1 issued pursuant to the b Exhibit 10.2 MIFID II PRODUCT GOVERNANCE / RETAIL INVESTORS, PROFESSIONAL INVESTORS AND ECPS TARGET MARKET – Solely for the purposes of each manufacturer’s product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties, professional clients and retail clients, each as defined in Directive
April 10, 2025	EX-99.1	Fresenius Medical Care AG Hof (Saale) ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Invitation to the Annual General Meeting Exhibit 99.1 Convenience Translation Fresenius Medical Care AG Hof (Saale) ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Invitation to the Annual General Meeting We hereby invite our shareholders to the Annual General Meeting of Fresenius Medical Care AG (hereinafter also “Company”). The General Meeting will be held as an in-person meeting on Thursday, 22 May 2025 at 10:
April 10, 2025	EX-99.4	Explanatory Report of the Management Board to the 2025 Annual General Meeting of Fresenius Medical Care AG on the information pursuant to Sections 289a, 315a of the German Commercial Code Exhibit 99.4 Convenience Translation Explanatory Report of the Management Board to the 2025 Annual General Meeting of Fresenius Medical Care AG on the information pursuant to Sections 289a, 315a of the German Commercial Code The information contained in the management report to the consolidated financial statements and the annual financial statements of Fresenius Medical Care AG (the Company) for
April 10, 2025	EX-99.5	Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York Mellon, as Depositary Bank Must be received prior to 5:00 p.m. EDT on May 12, 2025 (the “Cutoff Date”) The undersigned registered hold Exhibit 99.5 Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York Mellon, as Depositary Bank Must be received prior to 5:00 p.m. EDT on May 12, 2025 (the “Cutoff Date”) The undersigned registered holder of one or more American Depositary Receipts (“Receipts”) of Fresenius Medical Care AG (the “Company”) hereby requests and instructs Th
April 10, 2025	EX-99.3	Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG for the Fiscal Year 2024 Exhibit 99.3 Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG for the Fiscal Year 2024 Dear Shareholders, Fresenius Medical Care successfully completed its first full fiscal year following its change in legal form to a stock corporation. The year 2024 was marked by dynamic developments and significant geopolitical and geo-economic changes. Nevertheless, the glob
April 10, 2025	EX-99.2	Fresenius Medical Care AG Compensation Report for the fiscal year 2024 Exhibit 99.2 Fresenius Medical Care AG Compensation Report for the fiscal year 2024 Table of contents Introduction 3 The Fiscal Year in retrospect 4 Business performance and economic environment 4 Short-term incentive target achievement 4 Long-term incentive target achievement for the performance period ending at the end of the Fiscal Year 4 Compensation-relevant changes for the Management Board 5
April 10, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
April 8, 2025	EX-99.1	XS2178769076 / 217876907 / A289N2 Exhibit 99.1 NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERSON RESIDENT OR
April 8, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
April 2, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
April 2, 2025	EX-99.1	Maximum Acceptance Amount Exhibit 99.1 NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES") OR IN OR INTO OR TO ANY PERSON RESIDENT OR
April 1, 2025	EX-99.1	Fresenius Medical Care places bonds with a volume of 1.1 billion euros Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Sven Jacobsen T +49 171 28 79 127 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609
April 1, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
February 25, 2025	EX-13.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Martin Fischer, Chief Financial Off
February 25, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 25, 2025	EX-4.3	Lease Agreement for Office Facilities Exhibit 4.3 Lease Agreement for Office Facilities This Agreement is entered into between (1) Fresenius SE & Co. KGaA, with business address at Else-Kröner-Straße 1, 61352 Bad Homburg v. d. Höhe and registered with the commercial register of the local court of Bad Homburg v. d. Höhe under HRB 11852 – the “Landlord” – and (2) Fresenius Medical Care AG & Co. KGaA, with business address at Else-Kröner
February 25, 2025	EX-12.2	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Martin Fischer, certify that: 1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde
February 25, 2025	EX-2.16	AMENDMENT AND RESTATEMENT AGREEMENT dated 26 November 2024 FRESENIUS MEDICAL CARE AG BANK OF AMERICA EUROPE DAC as Agent relating to the EUR 2,000,000,000 REVOLVING FACILITY AGREEMENT originally dated 1 July 2021 Exhibit 2.16 AMENDMENT AND RESTATEMENT AGREEMENT dated 26 November 2024 between FRESENIUS MEDICAL CARE AG and BANK OF AMERICA EUROPE DAC as Agent and OTHERS relating to the EUR 2,000,000,000 REVOLVING FACILITY AGREEMENT originally dated 1 July 2021 Page 1/13 TABLE OF CONTENTS Section 1 Definitions and Interpretation 3 1.1 Definitions 3 1.2 Incorporation of defined terms 4 1.3 Designation 4 Section
February 25, 2025	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
February 25, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 25, 2025	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Helen Giza, Chief Executive Officer
February 25, 2025	EX-12.1	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Helen Giza, certify that: 1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh
February 25, 2025	EX-2.1	EX-2.1 Exhibit 2.1 Description of Securities The following description of the share capital of Fresenius Medical Care AG (the Company or FME AG) constitutes Exhibit 2.1, the “Description of Securities” required to be filed as an Exhibit to the Company’s Annual Report on Form 20-F. In accordance with paragraph 2(d) of the Instructions as to Exhibits in Form 20-F, it contains the information required by It
February 25, 2025	EX-99.1	Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025 Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025 · Organic revenue growth1 of
February 25, 2025	EX-11.2	Global Code of Conduct Exhibit 11.2 Global Code of Conduct for Business Partners 1 Content Letter from Management 4 1. Ethics and Business Integrity 5 1.1 Compliance with Applicable Laws and Regulations 5 1.2 Corruption, Bribery, and Fraud 5 1.3 Conflict of Interest 5 1.4 Money Laundering 5 1.5 Fair Competition 5 1.6 International Trade Controls 6 1.7 Tax Compliance 6 1.8 Conflict Minerals 6 2. Business Conduct in the H
February 25, 2025	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FOURTH QUARTER AND FULL YEAR 2024 February 25, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Bal Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FOURTH QUARTER AND FULL YEAR 2024 February 25, 2025 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results (outlook base) page 8
February 25, 2025	EX-4.2	Lease Agreement for Manufacturing Facilities Exhibit 4.2 Lease Agreement for Manufacturing Facilities This Agreement is entered into between (1) Fresenius Immobilien-Verwaltungs-GmbH & Co. Objekt St. Wendel KG, with business address at Else-Kröner-Straße 1, 61352 Bad Homburg v. d. Höhe and registered with the commercial register of the local court of Bad Homburg v. d. Höhe under HRA 3143 – the “Landlord” – and (2) Fresenius Medical Care Deut
February 25, 2025	EX-99.1	Fresenius Medical Care published form 20-F for the fiscal year 2024 Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care published form 20-F for the fiscal year 2024 Bad Homburg (February 25, 2025) - Fresenius Medical Care, the world’s l
February 25, 2025	EX-4.1	Lease Agreement for Manufacturing Facilities Exhibit 4.1 Lease Agreement for Manufacturing Facilities This Agreement is entered into between (1)Fresenius Immobilien-Verwaltungs-GmbH & Co. Objekt Schweinfurt KG, with business address at Else-Kröner-Straße 1, 61352 Bad Homburg v. d. Höhe and registered with the commercial register of the local court of Bad Homburg v. d. Höhe under HRA 3142 – the “Landlord” – and (2)Fresenius Medical Care Deuts
February 25, 2025	EX-4.4	Lease Agreement for Office Facilities - EK 3, Bad Homburg - Exhibit 4.4 Execution Copy Lease Agreement for Office Facilities - EK 3, Bad Homburg - This Agreement is entered into between (1)Fresenius SE & Co. KGaA, with business address at Else-Kröner-Straße 1, 61352 Bad Homburg v. d. Höhe and registered with the commercial register of the local court of Bad Homburg v. d. Höhe under HRB 11852 – the “Landlord” – and (2)Fresenius Medical Care Deutschland GmbH
February 24, 2025	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 24, 2025	EX-99.1	Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics Exhibit 99.1 PRESS RELEASE FME Media contact Christine Peters T +49 160 60 66 770 [email protected] FME Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Quest Media contact Jen Petrella T +1 973-520-2800 [email protected] Quest Contact for analysts and investors Shawn
December 20, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 20, 2024	EX-99.1	Fresenius Medical Care returns to Dax 40 Index Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care returns to Dax 40 Index Bad Homburg (December 20, 2024) - Fresenius Medical Care (FME), the world's leading provider
December 18, 2024	EX-99.2	List of 144A/Reg S Notes Exhibit 99.2 List of 144A/Reg S Notes · US$ 500,000,000 3.750% Notes due 2029 · US$ 1,000,000,000 2.375% Notes due 2031 · US$ 850,000,000 1.875% Notes due 2026 · US$ 650,000,000 3.000% Notes due 2031
December 18, 2024	EX-99.1	relating to EUR 500,000,000 1.500% Bonds 2018/2025 (XS1854532949) EUR 600,000,000 0.625% Bonds 2019/2026 (XS2084497705) EUR 500,000,000 1.250% Bonds 2019/2029 (XS2084488209) EUR 500,000,000 1.000% Bonds 2020/2026 (XS2178769076) EUR 750,000,000 1.500% Exhibit 99.1 Notice relating to EUR 500,000,000 1.500% Bonds 2018/2025 (XS1854532949) EUR 600,000,000 0.625% Bonds 2019/2026 (XS2084497705) EUR 500,000,000 1.250% Bonds 2019/2029 (XS2084488209) EUR 500,000,000 1.000% Bonds 2020/2026 (XS2178769076) EUR 750,000,000 1.500% Bonds 2020/2030 (XS2178769159) EUR 750,000,000 3.875% Bonds 2022/2027 (XS2530444624) issued by Fresenius Medical Care AG (formerl
December 18, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 12, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 12, 2024	EX-99.1	Convenience translation Fresenius Medical Care AG ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to section 248a sentence 1 of the German Stock Corporation Act (Aktiengesetz – AktG) Exhibit 99.1 Convenience translation Fresenius Medical Care AG Hof ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to section 248a sentence 1 of the German Stock Corporation Act (Aktiengesetz – AktG) In accordance with section 248a sentence 1 AktG, we hereby announce the following: The action for defective resolution (Beschlussmängelklageverfahren) br
November 14, 2024	SC 13G	FMS / Fresenius Medical Care AG - Depositary Receipt (Common Stock) / HARRIS ASSOCIATES L P Passive Investment SC 13G 1 formsc13g-11142024091150.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Fresenius Medical Care AG (Name of Issuer) Ordinary Shares, no par value â‚¬1.00 (Title of Class of Securities) 358029106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 5, 2024	EX-99.1	Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024 Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024 · Organic revenue growth of +2% supported
November 5, 2024	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2024 November 5, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2024 November 5, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results (outlook base) p
November 5, 2024	EX-10.4	Fresenius Medical Care AG Long-Term Incentive Plan 2024+ Exhibit 10.4 Non-MB Long-Term Incentive Plan 2024+ and July Grant 2024” Annex I to Voting Letter “Non-MB Long-Term Incentive Plan 2024+ and July Grant 2024” Management Board of Fresenius Medical Care AG Fresenius Medical Care AG Long-Term Incentive Plan 2024+ Page 1/19 TABLE OF CONTENTS CLAUSE PAGE 1. PREAMBLE AND PURPOSE 3 2. ELIGIBILITY TO RECEIVE PERFORMANCE SHARES 3 3. PERFORMANCE SHARES 4 4.
November 5, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
November 5, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024. Commission file number: 001- Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024. Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant’s name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Add
July 30, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024 • Organic revenue growth of +2.3% sup
July 30, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024. Commission file number: 001-3274 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024. Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant’s name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Address
July 30, 2024	EX-1.1	– NON-BINDING CONVENIENCE TRANSLATION – ARTICLES OF ASSOCIATION OF FRESENIUS MEDICAL CARE AG GENERAL TERMS Exhibit 1.1 – NON-BINDING CONVENIENCE TRANSLATION – ARTICLES OF ASSOCIATION OF FRESENIUS MEDICAL CARE AG I. GENERAL TERMS Article 1 Name and Registered Office (1) The name of the Company is: Fresenius Medical Care AG (2) The registered office of the Company is in Hof (Saale). Article 2 Objects of the Company (1) The objects of the Company are: a) the development, production and distribution of, as
July 30, 2024	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2024 July 30, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2024 July 30, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results (outlook base) page
July 30, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Ind
July 30, 2024	EX-10.3	Fresenius Medical Care AG Management Board Long-Term Incentive Plan (MB LTIP 2024) Exhibit 10.3 Exhibit to the Fresenius Medical Care AG Compensation Committee Meeting Presentation “Information Topics on Management Board Compensation Matters” on May 15, 2024 Fresenius Medical Care AG Management Board Long-Term Incentive Plan 2024+ (MB LTIP 2024) STRICTLY CONFIDENTIAL PLAN CONDITIONS – MANAGEMENT BOARD LONG-TERM INCENTIVE PLAN 2024+ PAGE 1/24 TABLE OF CONTENTS CLAUSE PAGE 1. PREA
June 28, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit
May 28, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG (Exact name of registrant as specified in its charter) Germany 001-32749 04-3534941 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Else-Kröner Strasse 1, Bad Homburg, Germany D-61352 (Addre
May 28, 2024	EX-1.01	Fresenius Medical Care AG Exhibit 1.01 Fresenius Medical Care AG Conflict Minerals Report This document, constituting Exhibit 1.01 to Form SD of Fresenius Medical Care AG, a German stock corporation (together with its subsidiaries, the Company, we, us, or our), is our Conflict Minerals Report for the year ended December 31, 2023, in accordance with Section 13p of the Securities Exchange Act of 1934, as amended and Rule 13p
May 23, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Moody’s and S&P change Fresenius Medical Care’s rating outlook to stable ● The change of the rating outlook reflects the company’s progress
May 23, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 16, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 16, 2024	EX-99.1	Media Contact Exhibit 99.1 Press Release Media Contact Christine Peters T +49 160 60 66 770 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com/de Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitio
May 7, 2024	EX-99.1	Fresenius Medical Care starts the year with strong earnings growth Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care starts the year with strong earnings growth · Solid revenue1 growth of 4% driven by both segments Care Delivery and
May 7, 2024	EX-10.2	Fresenius Medical Care AG Management Board Long-Term Incentive Plan (MB LTIP 2024) Exhibit 10.2 Exhibit E to the Fresenius Medical Care AG Supervisory Board Meeting Presentation “Management Board Compensation System 2024+” on March 14, 2024 Fresenius Medical Care AG Management Board Long-Term Incentive Plan 2024+ (MB LTIP 2024) STRICTLY CONFIDENTIAL PLAN CONDITIONS – MANAGEMENT BOARD LONG-TERM INCENTIVE PLAN 2024+ PAGE 1/24 TABLE OF CONTENTS CLAUSE PAGE 1. PREAMBLE AND PURPOSE 3
May 7, 2024	EX-10.1	Fresenius Medical Care AG Management Board Bonus Plan 2024+ (MBBP 2024+) Exhibit 10.1 Exhibit D to the Fresenius Medical Care AG Supervisory Board Meeting Presentation “Management Board Compensation System 2024+” on March 14, 2024 Fresenius Medical Care AG Management Board Bonus Plan 2024+ (MBBP 2024+) Strictly Confidential PLAN CONDITIONS – MANAGEMENT BOARD BONUS PLAN 2024+ PAGE 1/11 TABLE OF CONTENTS CLAUSE PAGE 1. PREAMBLE AND PURPOSE 3 2. TERM OF MBBP 2024+ 3 3. PA
May 7, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 7, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-32749 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant’s name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Address o
May 7, 2024	EX-99.2	Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FIRST QUARTER 2024 May 7, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cas Exhibit 99.2 Fresenius Medical Care AG COMPLETE OVERVIEW OF THE FIRST QUARTER 2024 May 7, 2024 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results (outlook base) page 8 Outlook 2024 page 9 D
May 3, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) Indi
May 3, 2024	EX-99.1	24-8764 Fresenius Medical Register VIF Proof 2 Annual General Meeting of Fresenius Medical Care AG Date: May 16, 2024 See Instructions On Reverse Side. Please make your marks like this: x Use pen only • Mark, sign and date your Voting Instruction For Exhibit 99.1 24-8764 Fresenius Medical Register VIF Proof 2 Annual General Meeting of Fresenius Medical Care AG Date: May 16, 2024 See Instructions On Reverse Side. Please make your marks like this: x Use pen only • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. • Return your Voting Instruction Form in the postage-paid envelope provided. MAIL Please Sign H
March 28, 2024	EX-99.3	Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG for the Fiscal Year 2023 Exhibit 99.3 Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG for the Fiscal Year 2023 Dear Shareholders, We reflect on an eventful year, one that Fresenius Medical Care AG has successfully completed. Persistent geopolitical conflicts and a challenging macroeconomic environment have characterized the past year and thus influenced the health care market. Rapid de
March 28, 2024	EX-99.2	Fresenius Medical Care AG Compensation Report for the 2023 fiscal year Exhibit 99.2 Fresenius Medical Care AG Compensation Report for the 2023 fiscal year Table of contents Introduction 3 The Fiscal Year in retrospect 3 Business performance and economic environment 3 Short-term incentive target achievement for the Fiscal Year 4 Long-term incentive target achievement for the performance period ending at the end of the Fiscal Year 4 Compensation-relevant changes in the
March 28, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
March 28, 2024	EX-99.4	Explanatory report by the Management Board of Fresenius Medical Care AG on the information pursuant to Sections 289a, 315a of the German Commercial Code (HGB) Exhibit 99.4 Convenience Translation Explanatory report by the Management Board of Fresenius Medical Care AG on the information pursuant to Sections 289a, 315a of the German Commercial Code (HGB) The information contained in the management report to the consolidated financial statements and the annual financial statements of Fresenius Medical Care AG for fiscal year 2023 according to Sections 289a
March 28, 2024	EX-99.1	If the number of no-par value shares entitled to dividend for fiscal year 2023 changes prior to the Annual General Meeting, the Annual General Meeting will be presented with a proposal that will be adjusted accordingly with an unchanged dividend of E Exhibit 99.1 Fresenius Medical Care AG Hof (Saale) ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Invitation to the Annual General Meeting We hereby invite our shareholders to the Annual General Meeting of Fresenius Medical Care AG (hereinafter also “Company”). The General Meeting will be held as a physical meeting on Thursday, 16 May 2024 at 10:00 hours Central European
March 13, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources · Effectiv
March 13, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
March 5, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Ilia Kürten T +49 6172 268 59 66 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile,
March 5, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices) In
February 20, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 20, 2024	EX-99.2	Statement of earnings in € million, except share data 2023 2022 Change Change at cc 2023 2022 Change Change at cc Total revenue 4,988 4,997 -0.2% 7.4% 19,454 19,398 0.3% 5.5% Costs of revenue 3,638 3,766 -3.4% 4.2% 14,529 14,504 0.2% 5.6% Selling, ge Exhibit 99.2 Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 Outlook 2024 page 9 Disclaimer Copyright by Fresenius Medical Care AG email: [email protected] phone: +49 6172 609 2525 Revenue development by segment Reconciliation results excl. special items This release contains forward-looking statement
February 20, 2024	EX-13.1	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Helen Giza, Chief Executive Officer
February 20, 2024	EX-4.4	Integration of TLA Amendment into GSA Structure © Fresenius SE & Co. KGaA 2 • GSA to confirm that the TLA remains in full force after Conversion Effective Date, subject to amendments as set forth in a new schedule to the GSA. • In the interest of tim Exhibit 4.4 Amendment to the Trademark License Agreement Project Gordian Bad Homburg, 27 November 2023 Integration of TLA Amendment into GSA Structure © Fresenius SE & Co. KGaA 2 • GSA to confirm that the TLA remains in full force after Conversion Effective Date, subject to amendments as set forth in a new schedule to the GSA. • In the interest of time, Schedule to set forth the amendments as per
February 20, 2024	EX-4.18	Table of Contents Exhibit 4.18 EXECUTION VERSION Privileged and Confidential Group Separation Agreement relating to the deconsolidation of Fresenius Medical Care AG & Co. KGaA from Fresenius SE & Co. KGaA Dated 30 November 2023 FRESENIUS SE & CO. KGAA and FRESENIUS MEDICAL CARE AG & CO. KGAA EXECUTION VERSION Table of Contents Clause Page 1 Definitions and Interpretation 2 2 Separation 2 2.1 Implementation of Separ
February 20, 2024	EX-97	FOR INTERNAL USE ONLY Exhibit 97 Global Incentive-Based Compensation Recovery Policy Type: 2 Policy Version No.
February 20, 2024	EX-2.1	Description of Securities Exhibit 2.1 Description of Securities The following description of the share capital of Fresenius Medical Care AG (the Company or FME AG) constitutes Exhibit 2.1, the “Description of Securities” required to be filed as an Exhibit to the Company’s Annual Report on Form 20-F. In accordance with paragraph 2(d) of the Instructions as to Exhibits in Form 20-F, it contains the information required by It
February 20, 2024	EX-4.20	INSURANCE BROKERAGE AGREEMENT dated November 2023 Exhibit 4.20 INSURANCE BROKERAGE AGREEMENT dated November 2023 between: Fresenius Medical Care AG & Co. KGaA, Else-Kröner-Straße 1, 61352 Bad Homburg v.d. Höhe, Deutschland - hereinafter referred to as the “Company”, and: Fresenius Versicherungsvermittlungs GmbH, Else-Kröner-Straße 1, 61352 Bad Homburg v.d. Höhe, Deutschland - hereinafter referred to as the “Broker”, - hereinafter, the Company and
February 20, 2024	EX-12.1	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Helen Giza, certify that: 1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh
February 20, 2024	EX-13.2	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG (the Company) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Martin Fischer, Chief Financial Off
February 20, 2024	EX-99.1	February 20, 2024 Press Release Media contact Christine Peters T +49 160 6066 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com February 20, 2024 Fresenius Medical Care published form 20-F for the fiscal year 2023 Fresenius Medical Care, the world’s leading provider of products an
February 20, 2024	EX-4.12	Fresenius Medical Care AG & Co. KGaA Long Term Incentive Plan 2022+ Amended version as of June 27, 2023 Exhibit 4.12 EXHIBIT H to Presentation “Global Total Rewards: Long-Term Incentive Plans” Management Board Meeting – June 27, 2023 Management Board of Fresenius Medical Care Management AG Fresenius Medical Care AG & Co. KGaA Long Term Incentive Plan 2022+ Amended version as of June 27, 2023 Page 1/18 TABLE OF CONTENTS CLAUSE PAGE 1. PREAMBLE AND PURPOSE 3 2. ELIGIBILITY TO RECEIVE PERFORMANCE SHARE
February 20, 2024	EX-4.19	- signatures on next page - Exhibit 4.19 EXECUTION VERSION Privileged and Confidential Master Agreement for Transitional Services relating to the deconsolidation of Fresenius Medical Care AG & Co. KGaA Dated 30 November 2023 FRESENIUS SE & CO. KGAA and FRESENIUS MEDICAL CARE AG & CO. KGAA A50902547/20.0/30 Nov 2023 EXECUTION VERSION Contents Clause Page Preamble 1 1 Definitions and Interpretation 1 2 Structure and Individual
February 20, 2024	EX-1.1	– NON-BINDING CONVENIENCE TRANSLATION – ARTICLES OF ASSOCIATION OF FRESENIUS MEDICAL CARE AG GENERAL TERMS Exhibit 1.1 – NON-BINDING CONVENIENCE TRANSLATION – ARTICLES OF ASSOCIATION OF FRESENIUS MEDICAL CARE AG I. GENERAL TERMS Article 1 Name and Registered Office (1) The name of the Company is: Fresenius Medical Care AG (2) The registered office of the Company is in Hof (Saale). Article 2 Objects of the Company (1) The objects of the Company are: a) the development, production and distribution of, as
February 20, 2024	EX-11.3	Global Insider Policy Exhibit 11.3 Global Insider Policy Type: 2 Policy Version No.: 1 Reference No.: 10203 Scope: FME Group (All Fresenius Medical Care AG & Co. KGaA wholly or majority-owned entities and organizational units) Out of Scope: n/a Target Group: n/a Publication Date: 28/February/2023 Effective Date: 4 weeks after publication Status: Published Owner’s Department: Global Legal Approver’s Position: FME Manage
February 20, 2024	EX-2.2	FRESENIUS MEDICAL CARE AG THE BANK OF NEW YORK MELLON As Depositary OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Amended and Restated Deposit Agreement November 30, 2023 Exhibit 2.2 FRESENIUS MEDICAL CARE AG AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Amended and Restated Deposit Agreement November 30, 2023 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 2 SECTION 1.01. American Depositary Shares. 2 SECTION 1.02. Commission. 3 SECTION 1.03. Company. 3 SECTION 1.04. Custodian. 3 SECTION 1.05. Deliver; Surrender. 3 SEC
February 20, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 20, 2024	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
February 20, 2024	EX-12.2	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Martin Fischer, certify that: 1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde
February 20, 2024	EX-99.1	Page 9/11 Page 10/11 Page 11/11 Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 6066 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com February 20, 2024 Fresenius Medical Care delivers on commitments in a year of fundamental transformation - Revenue growth of 5% in 2023 driv
February 20, 2024	EX-4.17	__________________________________________ Project Gordian Framework Agreement in Relation to the Separation of Fresenius Medical Care Management AG Exhibit 4.17 Execution Version [*] indicates portions omitted as information that is both not material and of the type that the registrant treats as private or confidential. Project Gordian Framework Agreement in Relation to the Separation of Fresenius Medical Care Management AG Project Gordian Framework Agreement in Relation to the Separation of Fresenius Medical Care Management AG THIS FRAMEWORK
February 13, 2024	SC 13G/A	FMS / Fresenius Medical Care AG - Depositary Receipt (Common Stock) / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d772544dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1 )* FRESENIUS MEDICAL CARE AG (Name of Issuer) Ordinary Shares and American Depositary Shares (Title of Class of Securities) 358029106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State
February 9, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Emanuela Cariolagian T +1 213 706 0051 [email protected] Contact for analysts and investors Ilia Kürten T +49 6172 268 59 66 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care Brings Industry-Leading Dialysis The
February 9, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 5, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
February 5, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Ilia Kürten T +49 6172 268 59 66 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board Bad Homburg (February 5, 2024) Fresenius Medical Care (
January 30, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 30, 2024 As filed with the Securities and Exchange Commission on January 30, 2024 No. 333-189721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Fresenius Medical Care AG (Exact name of registrant as specified in its charter) Germany 04-3534941 (State or other jurisdiction of incorpora
January 8, 2024	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Christine Peters T +49 151 215 275 19 [email protected] Contact for analysts and investors Ilia Kürten T +49 6172 6089 6253 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions · Divestments in 2023 are important milestones
January 8, 2024	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission file number: 001-32749 FRESENIUS MED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 7, 2023	EX-99.2	Fresenius Medical Care AG Hof (Saale) Notification by Management Board on the composition of the Supervisory Board of Fresenius Medical Care AG pursuant to Section 197 sentence 3 UmwG in conjunction with Sections 31 para. 3, 97 AktG Exhibit 99.2 English translation Fresenius Medical Care AG Hof (Saale) Notification by Management Board on the composition of the Supervisory Board of Fresenius Medical Care AG pursuant to Section 197 sentence 3 UmwG in conjunction with Sections 31 para. 3, 97 AktG The Extraordinary General Meeting of Fresenius Medical Care AG & Co. KGaA ("FME KGaA") resolved on July 14, 2023 to convert FME KGaA i
December 7, 2023	EX-99.1	Fresenius Medical Care AG Notification of impending merger pursuant to section 62 (3) sentence 2 of the German Transformation Act Exhibit 99.1 Fresenius Medical Care AG Hof Notification of impending merger pursuant to section 62 (3) sentence 2 of the German Transformation Act Pursuant to section 62 (3) sentence 2 of the German Transformation Act (Umwandlungsgesetz – "UmwG"), the management board (Vorstand) of Fresenius Medical Care AG with its registered office in Hof (Saale), Germany, registered with the commercial register
December 7, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 7, 2023	SC 13D/A	FMS / Fresenius Medical Care AG - ADR / Fresenius SE & Co. KGaA - SC 13D/A Activist Investment SC 13D/A 1 ef20015734sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) FRESENIUS MEDICAL CARE AG (Name of Issuer) Ordinary Shares without par value (Title of Class of Securities) 358029 10 61 (CUSIP Number) Matthias Fenner, Esq. Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad H
December 6, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive offices)
December 1, 2023	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 12, 2023, pursuant to the provisions of Rule 12d2-2 (a).
November 30, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-32749 FRESENIUS MEDICAL CARE AG (Translation of registrant's name into English) Else-Kröner-Strasse 1 61346 Bad Homburg Germany (Address of principal e
November 30, 2023	EX-99.2	Media contact Exhibit 99.2 Press Release Media contact Sabine Blessing T +1 800 723 2384 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] www.freseniusmedicalcare.com Fresenius Medical Care completes change of legal form into a German stock corporation ● Change of legal form simplifies the corporate governance structure as a German stoc
November 30, 2023	EX-99.1	Retrieved on 30 Nov. 2023 at 0920 hours Exhibit 99.1 Commercial Register B of the Local Court of Hof Company Number HRB 6841 Page 1 of 1 Retrieved on 30 Nov. 2023 at 0920 hours Entry No. a) Name of the company b) Registered office, place of business, business address in Germany, authorized recipient, branch offices c) Purpose of the enterprise Share or nominal capital a) General provision for representation b) Board of management, manag
November 21, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executi
November 21, 2023	EX-99.2	November 21, 2023 Exhibit 99.2 Media Contact Leif Heussen Press Release T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com November 21, 2023 Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 ea
November 21, 2023	EX-99.1	AD HOC RELEASE Exhibit 99.1 AD HOC RELEASE Fresenius Medical Care AG & Co. KGaA: Favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised Bad Homburg, November 21, 2023. Fresenius Medical Care AG & Co. KGaA (the “Company”) through its subsidiary Fresenius Medical Care Holdings, Inc. (“FMCH”) resolved a legal dispute with the U.S.
November 13, 2023	EX-99.1	Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz) Exhibit 99.1 Fresenius Medical Care AG & Co. KGaA Hof ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz) Pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz), we announce that another action for
November 13, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive of
November 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission file number: 001-3 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant’s name into English) Else-Kröner Strasse 1 61346 Bad Homburg Ge
November 2, 2023	EX-1.1	Convenience translation Exhibit 1.1 Convenience translation 1 Articles of Association of Fresenius Medical Care AG & Co. KGaA I. General Terms Art. 1 Name and Registered Office (1)The Company is a partnership limited by shares (KGaA). The name of the Company is Fresenius Medical Care AG & Co. KGaA (2)The registered office of the Company is in Hof an der Saale. Art. 2 Objects of the Business (1)The objects of the Company
November 2, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executi
November 2, 2023	EX-99.1	Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company's outlook in € million, unaudited Operating performance excl. special items These items are Exhibit 99.1 Press Release Media contact Leif Heussen T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com November 1, 2023 Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months
November 2, 2023	EX-99.2	Statement of earnings in € million, except share data, unaudited 2023 2022 Change Change at cc 2023 2022 Change Change at cc Total revenue 4,936 5,096 -3.1% 6.6% 14,466 14,401 0.4% 4.9% Costs of revenue 3,707 3,853 -3.8% 6.4% 10,890 10,738 1.4% 6.1% Exhibit 99.2 Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 Outlook 2023 page 9 Disclaimer Fresenius Medical Care AG & Co. KGaA November 1, 2023 COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2023 Investor Relations Copyright by Fresenius Medical Care AG & Co. KGaA email: [email protected] phone: +49
November 1, 2023	EX-99.1	ADHOC RELEASE Exhibit 99.1 ADHOC RELEASE Fresenius Medical Care AG & Co. KGaA raises outlook for operating income in fiscal year 2023 Bad Homburg, November 1, 2023 \| Fresenius Medical Care AG & Co. KGaA ("Fresenius Medical Care” or the "Company") has decided today, to raise the outlook for operating income in fiscal year 2023. The background to the decision are the positive effects of the turnaround measures an
November 1, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executi
October 31, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission file number: 001-32749 FRESENIUS MED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executiv
October 31, 2023	EX-99.1	October 31, 2023 Exhibit 99.1 Press Release Media Contact Leif Heussen T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com October 31, 2023 Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery Fresenius Medical Care, the world's leading provider of prod
September 6, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
September 6, 2023	EX-99.1	Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz – AktG) Exhibit 99.1 Fresenius Medical Care AG & Co. KGaA Hof ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz – AktG) Pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation Act (Aktiengesetz – AktG), we announce that an a
August 2, 2023	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Leif Heussen T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com August 2, 2023 Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023 - Orga
August 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-327 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant’s name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germ
August 2, 2023	EX-99.2	Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2023 August 2, 2023 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Bal Exhibit 99.2 Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2023 August 2, 2023 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development by segment page 6 Key metrics page 7 Reconciliation results excl. special items pa
August 2, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission file number: 001-32749 FRESENIUS MEDI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive
July 14, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
July 14, 2023	EX-99.1	Media Contact Press Release Media Contact Steffen Rinas T +49 6172 608-6698 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com July 14, 2023 Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation § Extraordinary General Meeting approves conversion of Fresenius Medi
July 10, 2023	EX-99.1	FME SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC, INCLUDING THE INFORMATION STATEMENT/PROSPECTUS THAT IS PART OF THE REGISTRATION STATEMENT, AS THEY BECOME AVAILAB Exhibit 99.1 Press Release Media Contact Steffen Rinas T +49 6172 608-6698 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Under the U.S. Securities Act of 1933, as amended (the “Securities Act”), this press release may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA
July 10, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
June 29, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transit
June 6, 2023	424B3	INVITATION TO AN EXTRAORDINARY GENERAL MEETING ISIN: DE0005785802 ISIN: US3580291066 CUSIP: 358029106 TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-271081 INVITATION TO AN EXTRAORDINARY GENERAL MEETING ISIN: DE0005785802 ISIN: US3580291066 CUSIP: 358029106 We are pleased to invite our shareholders to participate in an extraordinary general meeting of Fresenius Medical Care AG & Co. KGaA (“FME KGaA” or the “Company” and together with its consolidated subsidiaries “FME Gr
June 5, 2023	425	Filed by Fresenius Medical Care AG & Co. KGaA Filed by Fresenius Medical Care AG & Co. KGaA (Registration No.333-271081), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended Press Release Media Contact Martin Kunze T +49 6172 608-2115 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com June 5, 2023 Under the U.S. Securi
June 5, 2023	425	EGM Website Q&A EGM Website Q&A Filed by Fresenius Medical Care AG & Co. KGaA (Registration No.333-271081), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended Under the U.S. Securities Act of 1933, as amended (the Securities Act), these Frequently asked questions may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA (the Company). The Company has filed a registratio
June 2, 2023	EX-99.1	Statement of earnings in € million, except share data, unaudited Three months ended March 31, Three months ended June 30, Three months ended Sept. 30, Three months ended Dec. 31, Six months ended June 30, Nine months ended Sept. 30, Twelve months end Exhibit 99.1 Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 - 9 page 10 Outlook 2023 page 11 Disclaimer Copyright by Fresenius Medical Care AG & Co. KGaA email: [email protected] phone: +49 6172 609 2525 Revenue development by segment Reconciliation results excl. special items This release contains forward-looking
June 2, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
June 2, 2023	CORRESP	June 2, 2023 June 2, 2023 VIA EDGAR Office of Industrial Applications and Services Division of Corporation Finance U.
June 2, 2023	EX-99.1	– NON-BINDING CONVENIENCE TRANSLATION – CONVERSION REPORT Fresenius Medical Care Management AG on the change of legal form Fresenius Medical Care AG & Co. KGaA into the legal form of a stock corporation (Aktiengesellschaft) under the laws of the Fede Exhibit 99.1 Filed by Fresenius Medical Care AG & Co. KGaA (Commission File No. 001-32749), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended This Exhibit consists of a convenience English translation of Fresenius Medical Care AG & Co. KGaA’s (FME) Conversion Report issued in connection with its a proposed conversion of the legal form of FME. Under the U.S. Securities Act
June 2, 2023	EX-99.1	23809 Fresenius Medical Register VIF Proof 5 FRESENIUS MEDICAL CARE AG & Co. KGaA Instructions to The Bank of New York Mellon, as Depositary Bank Must be received prior to 12:00 p.m. (noon) New York City time on July 3, 2023 (the “Cutoff Date”) The u Exhibit 99.1 23809 Fresenius Medical Register VIF Proof 5 Extraordinary General Meeting of Fresenius Medical Care AG & Co. KGaA Date: July, 14, 2023 See Instructions On Reverse Side. Please make your marks like this: x Use pen only • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. • Return your Voting Instruction Form in the postage-paid envelope provided.
June 2, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form F-4 (Form Type) Fresenius Medical Care AG & Co. KGaA . (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) Fresenius Medical Care AG & Co.
June 2, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
June 2, 2023	F-4/A	As filed with the Securities and Exchange Commission on June 2, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 2, 2023 Registration No.
May 31, 2023	EX-1.01	Fresenius Medical Care AG & Co. KGaA Exhibit 1.01 Fresenius Medical Care AG & Co. KGaA Conflict Minerals Report This document, constituting Exhibit 1.01 to Form SD of Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares (together with its subsidiaries, the Company, we, us, or our), is the Company’s Conflict Minerals Report for the reporting period January 1 to December 31, 2022, in accordance with Section 13p
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG & Co. KGaA (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG & Co. KGaA (Exact name of registrant as specified in its charter) Germany 001-32749 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) Else-Kröner Strasse 1, Bad Homburg, Germany
May 16, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive of
May 16, 2023	EX-99.1	Media Contact Exhibit 99.1 Press Release Media Contact Leif Heussen T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Under the U.S. Securities Act of 1933, as amended (the “Securities Act”), this press release may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA (
May 9, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-32749 FRESENIUS MEDICAL 6-K 1 tm2310519d26k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (
May 9, 2023	EX-99.1	unaudited20232022Operating performance excl. special itemsThese items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items.Revenue4,7044,548Operating income Exhibit 99.1 Press Release Media contact Leif Heussen T +49 6172 608-4030 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Under the U.S. Securities Act of 1933, as amended (the “Securities Act”), this press release may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA (
May 9, 2023	EX-10.3	Amendment No. 3 dated October 18, 2022 to Eighth Amended and Restated Transfer and Administration Agreement dated as of August 11, 2021. Exhibit 10.3 EXECUTION VERSION AMENDMENT NO. 3 Dated as of October 18, 2022 to EIGHTH AMENDED AND RESTATED TRANSFER AND ADMINISTRATION AGREEMENT Dated as of August 11, 2021 THIS AMENDMENT NO. 3 (this “Amendment”) dated as of October 18, 2022 is entered into by and among (i) NMC FUNDING CORPORATION, a Delaware corporation (the “Transferor”), (ii) NATIONAL MEDICAL CARE, INC., a Delaware corporation,
May 9, 2023	EX-10.1	Termination agreement between Fresenius Medical Care AG & Co. KGaA, as borrower, and Fresenius SE & Co. KGaA, as lender, of the €600 million uncommitted revolving credit facility agreement. Exhibit 10.1 21 APRIL 2023 TERMINATION AGREEMENT (Aufhebungsvereinbarung) between FRESENIUS MEDICAL CARE AG & CO. KGAA as Borrower and FRESENIUS SE & CO. KGAA as Lender CONTENTS CLAUSE PAGE 1. Definitions and Interpretation 3 2. Termination of the Uncommitted RCF, Confirmation 4 3. Further Assurance 4 4. Miscellaneous 4 5. Conclusion of this Agreement (Vertragsschluss) 5 6. Governing Law and Juris
May 9, 2023	EX-10.2	Amendment No. 2 dated August 26, 2022 to Eighth Amended and Restated Transfer and Administration Agreement dated as of August 11, 2021. Exhibit 10.2 Execution Copy AMENDMENT NO. 2 Dated as of August 26, 2022 to EIGHTH AMENDED AND RESTATED TRANSFER AND ADMINISTRATION AGREEMENT Dated as of August 11, 2021 THIS AMENDMENT NO. 2 (this “Amendment”) dated as of August 26, 2022 is entered into by and among (i) NMC FUNDING CORPORATION, a Delaware corporation (the “Transferor”), (ii) NATIONAL MEDICAL CARE, INC., a Delaware corporation, as c
May 9, 2023	EX-10.4	Amendment No. 4 dated February 27, 2023 to Eighth Amended and Restated Transfer and Administration Agreement dated as of August 11, 2021. Exhibit 10.4 EXECUTION VERSION AMENDMENT NO. 4 Dated as of February 27, 2023 to EIGHTH AMENDED AND RESTATED TRANSFER AND ADMINISTRATION AGREEMENT Dated as of August 11, 2021 THIS AMENDMENT NO. 4 (this “Amendment”) dated as of February 27, 2023 is entered into by and among (i) NMC FUNDING CORPORATION, a Delaware corporation (the “Transferor”), (ii) NATIONAL MEDICAL CARE, INC., a Delaware corporatio
May 9, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission file number: 001-32749 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant’s name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany
May 9, 2023	EX-99.2	Statement of earnings in € million, except share data, unaudited 2023 2022 Change Change at cc Total revenue 4,704 4,548 3.4% 1.7% Costs of revenue 3,555 3,374 5.4% 3.6% Selling, general and administrative expenses 782 790 -1.0% -3.2% Research and de Exhibit 99.2 Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 Outlook 2023 page 9 Disclaimer Copyright by Fresenius Medical Care AG & Co. KGaA email: [email protected] phone: +49 6172 609 2525 Revenue development by segment Reconciliation results excl. special items This release contains forward-looking statements t
April 19, 2023	FWP	© Copyright ▪ Fresenius Medical Care Capital Markets Day 2023 April 19, 2023 \| Virtual event Additional Information and Where to Find it. Fresenius Medical Care AG &Co. KGaA ("FME") has filed a registration statement (including an information stateme Issuer Free Writing Prospectus, dated April 19, 2023 Filed Pursuant to Rule 433 of the Securities Act of 1933 Relating to the Preliminary Prospectus filed Apri13, 2023 Registration No.
April 19, 2023	425	Fresenius Medical Care charts path to unlock value as the leading kidney care company Filed by Fresenius Medical Care AG & Co. KGaA (Commission File No. 001-32749), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended On April 19, 2023, Fresenius Medical Care AG & Co. KGaA (the “Company”) issued a Press Release announcing its unaudited full year results for the year ending December 31, 2022 and its unaudited first quarter results for the period ending March 31
April 13, 2023	EX-99.1	22930 Fresenius Medical Register VIF Proof 3 FRESENIUS MEDICAL CARE AG & Co. KGaA Instructions to The Bank of New York Mellon, as Depositary Bank Must be received prior to 12:00 p.m. New York City time on May 5, 2023 (the “Cutoff Date”) The undersign Exhibit 99.1 22930 Fresenius Medical Register VIF Proof 3 Annual General Meeting of Fresenius Medical Care AG & Co. KGaA Date: May 16, 2023 See Instructions On Reverse Side. Please make your marks like this: x Use pen only • Mark, sign and date your Voting Instruction Form. • Detach your Voting Instruction Form. • Return your Voting Instruction Form in the postage-paid envelope provided. MAIL Plea
April 13, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive
April 3, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) Fresenius Medical Care AG & Co.
April 3, 2023	F-4	As filed with the Securities and Exchange Commission on April 3, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 3, 2023 Registration No.
March 30, 2023	EX-99.4	Lease expense (1) Exhibit 99.4 Supplemental Information FOR HOLDERS OF AMERICAN DEPOSITARY SHARES TO ACCOMPANY THE INVITATION AND AGENDA FOR THE 2023 ANNUAL GENERAL MEETING In this document (1) “FMC AG & Co. KGaA,” the “Company,” “we,” “us” or “our” refer to both Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares and to Fresenius Medical Care AG & Co. KGaA and its subsidiaries on a consoli
March 30, 2023	EX-99.1	INVITATION TO THE ANNUAL GENERAL MEETING T U ES DAY, 1 6 M AY 2023 INVITATION 03 Invitation to the Annual General Meeting I. AGENDA 03 1. Presentation of the annual financial statements and consolidated financial statements each approved by the Super Exhibit 99.1 INVITATION TO THE ANNUAL GENERAL MEETING T U ES DAY, 1 6 M AY 2023 INVITATION 03 Invitation to the Annual General Meeting I. AGENDA 03 1. Presentation of the annual financial statements and consolidated financial statements each approved by the Supervisory Board, the manage-ment reports for Fresenius Medical Care AG & Co. KGaA and the group, the explanatory report by the General Partn
March 30, 2023	EX-99.3	Explanatory report of the General Partner on information according to Sec. 289a para. 1, Sec. 315a para. 1 of the German Commercial Code Exhibit 99.3 Convenience Translation Explanatory report of the General Partner on information according to Sec. 289a para. 1, Sec. 315a para. 1 of the German Commercial Code The information contained in the management report to the consolidated financial statements and the annual financial statements of Fresenius Medical Care AG & Co. KGaA for the fiscal year 2022 according to Sec. 289a para. 1, S
March 30, 2023	EX-99.2	Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG & Co. KGaA for the Fiscal Year 2022 Exhibit 99.2 Convenience translation Report by the Supervisory Board of Fresenius Medical Care AG & Co. KGaA for the Fiscal Year 2022 In the past fiscal year, Fresenius Medical Care operated in a challenging macroeconomic environment characterized by wage and general cost inflation, which affected all business segments of the company. In the U.S., Fresenius Medical Care faced a labor market situat
March 30, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission file number: 001-32749 FRESENIUS MEDIC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executive
March 22, 2023	SC 13D/A	FMS / Fresenius Medical Care AG & Co. KGaA - ADR / Fresenius SE & Co. KGaA - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) FRESENIUS MEDICAL CARE AG & CO. KGaA (Name of Issuer) Ordinary Shares without par value (Title of Class of Securities) 358029 10 61 (CUSIP Number) Matthias Fenner, Esq. Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany +49-6172
February 23, 2023	EX-99.1	February 23, 2023 Exhibit 99.1 Press Release Media Contact Martin Kunze T +49 6172 608-2115 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com February 23, 2023 Fresenius Medical Care published form 20-F for the fiscal year 2022 Fresenius Medical Care, the world’s leading provider of products and services for indi
February 23, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS ME SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executi
February 22, 2023	EX-13.1	Certification of Chief Executive Officer, Chair of the Management Board of the Company’s General Partner and Acting Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). (This Exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate it by reference.) Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Fresenius Medical Care AG & Co. KGaA (the Company) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Helen Giza, Chief Execut
February 22, 2023	EX-14.1	Consent of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, independent registered public accounting firm (filed herewith) Exhibit 14.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-189721) of Fresenius Medical Care AG & Co. KGaA of our report dated February 22, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20F. Fran
February 22, 2023	EX-12.1	Certification of Chief Executive Officer, Chair of the Management Board of the Company’s General Partner and Acting Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Helen Giza, certify that: 1. I have reviewed this annual report on Form 20-F of Fresenius Medical Care AG & Co. KGaA (the Report); 2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th
February 22, 2023	EX-2.1	Description of Securities (filed herewith). Exhibit 2.1 Exhibit 2.1Description of Securities The following description of the share capital of Fresenius Medical Care AG & Co. KGaA (the Company or FMC AG & Co. KGaA) constitutes Exhibit 2.1, the “Description of Securities” required to be filed as an Exhibit to the Company’s Annual Report on Form 20-F. In accordance with paragraph 2(d) of the Instructions as to Exhibits in Form 20-F, it contai
February 22, 2023	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
February 22, 2023	EX-4.12	English convenience translation of the Appendix to the Fresenius Medical Care Management Board Long-Term Incentive Plan 2020 Target Values and Determination of Target Achievement for the Grants of Performance Shares in Fiscal Year 2023 (filed herewith). Exhibit 4.12 Fresenius Medical Care Management AG APPENDIX TO THE MANAGEMENT BOARD LONG TERM INCENTIVE PLAN 2020 (MB LTIP 2020) TARGET VALUES AND DETERMINATION OF TARGET ACHIEVEMENT FOR THE GRANTS OF PERFORMANCE SHARES IN FISCAL YEAR 2023 PAGE 1/5 Based on its resolution of January 2023 on the target values for the grants of Performance Shares in fiscal year 2023 under the Management Board Long Te
February 22, 2023	EX-4.13	English convenience translation of the Fresenius Medical Care & Co. KGaA Long-Term Incentive Plan 2022+ (filed herewith). Exhibit 4.13 Fresenius Medical Care AG & Co. KGaA Long Term Incentive Plan 2022+ Page 1/18 TABLE OF CONTENTS CLAUSE PAGE 1. PREAMBLE AND PURPOSE 3 2. ELIGIBILITY TO RECEIVE PERFORMANCE SHARES 3 3. PERFORMANCE SHARES 4 4. GRANT OF PERFORMANCE SHARES 4 5. PERFORMANCE TARGETS, TARGET ACHIEVEMENT AND PERFORMANCE PERIOD / APPENDICES 5 6. VESTING OF PERFORMANCE SHARES 6 7. SETTLEMENT OF PERFORMANCE SHAR
February 22, 2023	EX-4.11	English convenience translation of the Appendix to the Fresenius Medical Care Management Board Long-Term Incentive Plan 2020 Target Values and Determination of Target Achievement for the Grants of Performance Shares in Fiscal Years 2022 and 2023 (filed herewith). Exhibit 4.11 Fresenius Medical Care Management AG APPENDIX TO THE MANAGEMENT BOARD LONG TERM INCENTIVE PLAN 2020 (MB LTIP 2020) TARGET VALUES AND DETERMINATION OF TARGET ACHIEVEMENT FOR THE GRANTS OF PERFORMANCE SHARES IN FISCAL YEARS 2022 AND 2023 PAGE 1/5 Based on its resolution of December 2021 on the target values for the grants of Performance Shares in fiscal years 2022 and 2023 under the Man
February 21, 2023	425	Fresenius Medical Care AG & Co. KGaA initiates concrete plans for change of the legal form into a German stock corporation Filed by Fresenius Medical Care AG & Co. KGaA (Commission File No. 001-32749), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended This filing consists of an Ad-Hoc notification, press release and investor presentation issued by Fresenius Medical Care AG & Co. KGaA on February 21, 2023 in connection with its announcement of a proposed conversion of the legal form of Freseniu
February 21, 2023	EX-99.2	Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE FOURTH QUARTER AND FULL YEAR 2022 February 21, 2023 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balanc Exhibit 99.2 Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE FOURTH QUARTER AND FULL YEAR 2022 February 21, 2023 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development page 6 Key metrics page 7 Reconciliation results excl. special items page 8 Outlook 2
February 21, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS ME 6-K 1 tm232437d36k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germa
February 21, 2023	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Martin Kunze T +49 6172 608-2115 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com Under the U.S. Securities Act of 1933, as amended (the “Securities Act”), this press release may be deemed to be offering material of Fresenius Medical Care AG & Co. KGaA (
February 14, 2023	SC 13G	FMS / Fresenius Medical Care AG & Co KGaA / DODGE & COX - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* FRESENIUS MEDICAL CARE AG & Co. KGaA (Name of Issuer) Ordinary Shares and American Depositary Shares (Title of Class of Securities) 358029106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp
February 9, 2023	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS ME 6-K 1 tm236122d16k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germa
February 9, 2023	EX-99.1	Ad-hoc announcement according to Art. 17 (1) MAR Exhibit 99.1 Ad-hoc announcement according to Art. 17 (1) MAR February 9th, 2023 Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation Following press reports, Fresenius Medical Care AG & Co. KGaA (“Company”) confirms that Fresenius SE & Co. KGaA, which is holding approx. 32% of the shares of the Company
December 6, 2022	EX-99.1	December 5 Exhibit 99.1 Ad-hoc announcement according to Art. 17 (1) MAR Media contact Steffen Rinas T +49 6172 608-6698 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com December 5th, 2022 Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet
December 6, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission file number: 001-32749 FRESENIUS ME 6-K 1 tm2232115d16k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germ
December 6, 2022	EX-99.2	December 5, 2022 Exhibit 99.2 Press Release Media Contact Steffen Rinas T +49 6172 608-6698 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com December 5, 2022 Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care Helen Giza (54) has been appointed Chief Executive Officer of Fresenius Medi
October 31, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission file number: 001-32749 FRESENIUS MED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kröner Strasse 1 61346 Bad Homburg Germany (Address of principal executiv
October 31, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission file number: 001-32749 FRESENIUS Table of Contents ? ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER ? PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission file number: 001-32749 ? FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant?s name into English) ? Else-Kr?ner Strasse 1 61346 Bad Homburg Ger
October 31, 2022	EX-99.3	Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2022 October 30, 2022 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.3 Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE THIRD QUARTER AND FIRST NINE MONTHS 2022 October 30, 2022 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development page 6 Key metrics page 7 Quality data page 8 Reconciliation results excl. spec
October 31, 2022	EX-99.2	October 30, 2022 Exhibit 99.2 Press Release Media contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com October 30, 2022 Fresenius Medical Care revises financial outlook for full year 2022 due to delayed effects from improvements in North American Services business in challeng
October 31, 2022	EX-99.1	Media contact EX-99.1 2 tm2229266d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ad-hoc announcement according to Art. 17 (1) MAR Media contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com October 30th, 2022 Fresenius Medical Care AG & Co. KGaA extends net income target range for f
October 31, 2022	EX-10.3	Final Terms dated September 15, 2022 for EUR 750,000,000 3.875% Fixed Rate Euro-Denominated Bonds due 2027. Exhibit 10.3 MIFID II PRODUCT GOVERNANCE / RETAIL INVESTORS, PROFESSIONAL INVESTORS AND ECPS TARGET MARKET ? Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties, professional clients and retail clients, each as defined in Directive
September 30, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS M SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal execut
September 13, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS M SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal execut
September 13, 2022	EX-99.1	September 12, 2022 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media Contact Matthias Link T +49 6172 609-2872 [email protected] Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com September 12, 2022 Fresenius Medic
September 1, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS M SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal execut
August 24, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission file number: 001-32749 FRESENIUS MEDI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal executive
August 24, 2022	EX-99.1	Media Contact Exhibit 99.1 Press Release Media Contact Martin Kunze T +49 6172 608-2115 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com August 24, 2022 Fresenius Medical Care closes three-way merger and creates premier value-based kidney care provider in the U.S. Fresenius Medical Care, the world's leading
August 2, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission file number: 001-32749 FRESENIUS MEDI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal executive
August 2, 2022	EX-99.1	Media contact Exhibit 99.1 Press Release Media contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com August 2, 2022 Fresenius Medical Care publishes financial results for the second quarter and first half of 2022 in line with preliminary results - Results unchanged compared
August 2, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission file number: 001-32749 FRESENIUS M Table of Contents ? ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER ? PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission file number: 001-32749 ? FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant?s name into English) ? Else-Kr?ner Strasse 1 61346 Bad Homburg Germ
August 2, 2022	EX-99.2	Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2022 August 2, 2022 Investor Relations phone: +49 6172 609 2525 email: [email protected] Exhibit 99.2 Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2022 August 2, 2022 Investor Relations phone: +49 6172 609 2525 email: [email protected] Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 Revenue development page 6 Key metrics page 7 Quality data page 8 Reconciliation results excl. special
August 2, 2022	EX-10.2	EUR 600,000,000 Uncommitted Revolving Credit Facility Agreement dated June 26, 2022, among the Registrant as borrower and Fresenius SE & Co. KGaA as lender (incorporated by reference to Exhibit 10.2 to the Registrant’s Report on Form 6-K for the month of August 2022, furnished August 2, 2022). Exhibit 10.2 ? ? EUR 600,000,000 UNCOMMITTED REVOLVING CREDIT FACILITY AGREEMENT This EUR 600,000,000 uncommitted revolving credit facility agreement (the "Agreement") is effective as of 1 August 2022 and made between: 1. FRESENIUS MEDICAL CARE AG & CO. KGAA, a German partnership limited by shares (Kommanditgesellschaft auf Aktien) organised under the laws of Germany, registered with the commercia
August 2, 2022	EX-10.1	Amendment dated June 8, 2022 to the Sustainability-Linked Revolving Credit Facility Agreement dated July 1, 2021 between the Company and Fresenius Medical Care Holdings, Inc. as borrowers and guarantors, and the financial institutions party thereto in their respective capacities as Coordinators, Bookrunners, Arrangers, Original Lenders (including their respective Original Lending Affiliates), Sustainability Agent, Agent and Swingline Agent. Exhibit 10.1 BENCHMARK RATE CHANGE REQUEST LETTER To: Bank of America Europe DAC 26 Elmfield Road, Bromley Kent BR1 1LR as Agent under the Agreement (as defined below) Attn.: Loans Agency Email: [email protected] From: Fresenius Medical Care AG & Co. KGaA Else-Kr?ner-Strasse 1 61352 Bad Homburg and Fresenius Medical Care Holding, Inc. as Borrowers under the Agreement (as defin
July 28, 2022	EX-99.1	Media contact Exhibit 99.1 Ad-hoc announcement according to Art. 17 (1) MAR Media contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com July 27th, 2022 Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation
July 28, 2022	EX-99.2	Media contact Exhibit 99.2 Press Release Media contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com July 27th, 2022 Fresenius Medical Care cuts outlook for FY 2022 due to increased headwinds from U.S. labor market and global inflation, and withdraws 2025 targets - Outlook:
July 28, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission file number: 001-32749 FRESENIUS MEDICA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal executive o
June 29, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 11-K 1 tm2219476d111k.htm FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(D) OF THE SECURITIES
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG & Co. KGaA (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Fresenius Medical Care AG & Co. KGaA (Exact name of registrant as specified in its charter) Germany 001-32749 Not applicable (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) Else-Kr?ner Strasse 1, Bad Homburg, Germany
May 31, 2022	EX-1.01	Exhibit 1.01 — Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. Exhibit 1.01 Fresenius Medical Care AG & Co. KGaA Conflict Minerals Report This document, constituting Exhibit 1.01 to Form SD of Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares (together with its subsidiaries, the ?Company,? ?we,? ?us,? or ?our?), is the Company?s Conflict Minerals Report (?CMR?) for the reporting period January 1 to December 31, 2021 in accordance wi
May 17, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal executive of
May 17, 2022	EX-99.1	Audited consolidated financial statements of Fresenius Medical Care Holdings, Inc. and subsidiaries as of and for the years ended December 31, 2021 and 2020. Exhibit 99.1 FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Consolidated Financial Statements December 31, 2021 and 2020 FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Table of Contents Page(s) Report of Independent Auditors 1-2 Consolidated Balance Sheets as of December 31, 2021 and 2020 3 Consolidated Statements of Income for the years ended December 31, 2021 and 2020 Consolidate
May 12, 2022	EX-99.1	Media Contact Exhibit 99.1 Press Release Media Contact Matthias Link T +49 6172 609-2872 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 [email protected] www.freseniusmedicalcare.com May 12, 2022 Fresenius Medical Care: Growth drivers remain unchanged, Annual General Meeting approves 25th consecutive dividend increase Fresenius Medical Care, the world's
May 12, 2022	6-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission file number: 001-32749 FRESENIUS MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2022 Commission file number: 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant's name into English) Else-Kr?ner Strasse 1 61346 Bad Homburg Germany (Address of principal executive of

FMS / Fresenius Medical Care AG - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings